BioSpace News Archive

RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* as a new modality for treating all stages of cancer, announced the formation of a 10-member Scientific Advisory Board.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that Papillary disease (Cohort B), the second indication of its QUILT 3.032 Phase 2/3 study of intravesical BCG plus Anktiva in patients with BCG-unresponsive high-grade NMIBC (NCT03022825), also met its primary endpoints with disease-free survival of 57% of patients at 12 months.

Ambulero Inc., a biotechnology company developing new cell and gene therapy treatments for patients suffering from severe vascular disease, announced that the U.S. FDA’s Office For Orphan Products Development granted the company’s request for orphan drug status for its gene therapy candidate, AMB-301, to treat Buerger’s Disease, also known as Thromboangiitis Obliterans.

OmniVision Technologies, Inc., a leading developer of advanced digital imaging solutions, today announced the OVMed® OCHSA and OCHTA cable modules for single-use endoscope and catheters.

Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of Teneobio, Inc. (Teneobio).

Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today joins with the global Niemann-Pick Disease community in recognizing Niemann-Pick Disease Awareness Month,

Syneos Health®, the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2021 financial results on Wednesday, November 3rd, 2021, prior to its earnings call at 8:00 a.m. ET.

Tthe U.S. Food and Drug Administration issued a landmark proposal intended to improve access to and reduce the cost of hearing aid technology for millions of Americans.

Varian, a Siemens Healthineers company, a leading provider of cancer care technologies and solutions, will demonstrate the power of intelligent cancer care to shape the future of oncology during the 2021 American Society for Radiation Oncology (ASTRO) taking place in Chicago, Illinois, October 24-27.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, announced today that it has publicly filed an F-1 Registration Statement (File No.: 333-260338) with the U.S. Securities and Exchange Commission relating to a proposed U.S. initial public offering.